Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA4 | P22748 | 3/20 | 0.54 |
| ▸ | CA6 | P23280 | 3/20 | 0.54 |
| ▸ | CA5A | P35218 | 3/20 | 0.54 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA3 | P07451 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | SNCA | P37840 | 2/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906244 | 0.87 | APP (0.67) | APPMAPTEPHX2KDM4ECA12 | |
| SCHEMBL9906236 | 0.86 | MAPT (0.63) | APPMAPTEPHX2KDM4ECA12 | |
| SCHEMBL8531554 | 0.84 | ALDH1A1 (0.55) | APPMAPTEPHX2KDM4ECA12 | |
| SCHEMBL8521306 | 0.84 | MAPT (0.72) | APPMAPTEPHX2KDM4ECA12 | |
| SCHEMBL8520691 | 0.82 | ALDH1A1 (0.56) | APPMAPTEPHX2KDM4ECA12 | |
| SCHEMBL117018 | 0.82 | APP (0.60) | APPMAPTEPHX2KDM4ECA12 | |
| SCHEMBL1333222 | 0.78 | KDM4E (0.83) | APPMAPTEPHX2KDM4ECA12 | |
| Ferulate SCHEMBL28492960 | 0.78 | KDM4E (0.73) | APPMAPTEPHX2KDM4ECA12 | |
| SCHEMBL8531573 | 0.77 | ALDH1A1 (0.64) | APPMAPTEPHX2KDM4ECA12 | |
| SCHEMBL8520725 | 0.77 | MAPT (0.65) | APPMAPTEPHX2KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129818-A1 | Compositions and Methods for Treatment of Cardiovascular Disease | CARMEL BIOSCIENCES, INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2010124201-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE | INVASC THERAPEUTICS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129818-A1 | Compositions and Methods for Treatment of Cardiovascular Disease | APOB, LDLR, APOL1 | APP 1300/4885MAPT 1463/4885EPHX2 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.